Last reviewed · How we verify

Daratumumab plus Velcade Cyclophosphamide Dexamethasone

Stichting European Myeloma Network · Phase 2 active Small molecule

Daratumumab is a monoclonal antibody that targets CD38, a protein found on the surface of multiple myeloma cells, while Velcade is a proteasome inhibitor that blocks the action of proteasomes, which are responsible for breaking down proteins in cells, and Cyclophosphamide and Dexamethasone are chemotherapy drugs that kill cancer cells.

Daratumumab is a monoclonal antibody that targets CD38, a protein found on the surface of multiple myeloma cells, while Velcade is a proteasome inhibitor that blocks the action of proteasomes, which are responsible for breaking down proteins in cells, and Cyclophosphamide and Dexamethasone are chemotherapy drugs that kill cancer cells. Used for Treatment of multiple myeloma.

At a glance

Generic nameDaratumumab plus Velcade Cyclophosphamide Dexamethasone
SponsorStichting European Myeloma Network
Drug classMonoclonal antibody, Proteasome inhibitor, Chemotherapy
TargetCD38
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

Daratumumab works by binding to CD38 on the surface of multiple myeloma cells, marking them for destruction by the immune system. Velcade blocks the action of proteasomes, which are responsible for breaking down proteins in cells, leading to cell death. Cyclophosphamide and Dexamethasone are chemotherapy drugs that kill cancer cells by interfering with their DNA and cell division.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results